Your search found 3 Results
Directory of hormonal contraceptives. 2nd ed. Repertoire des contraceptifs hormonaux. Guia de anticonceptivos hormonales.
London, England, International Planned Parenthood Federation [IPPF], 1992. 92 p. (IPPF Medical Publications)IPPF updated its Directory of Hormonal Contraceptives in 1992. Several pharmaceutical manufacturers financed this 2nd edition. The directory has information printed in English, French, and Spanish. It is divided into 6 key parts: introduction, instructions on how to use the directory, contraceptive brand names, hormonal composition (codes/brand names), principal manufactures, and a list of the different types of hormonal contraceptives available for each country with a population of more than 100,000 people. Hormonal contraceptives covered in this directory include combined oral contraceptives (OCs) phasic OCs, continuous OCs injectables, and implants. In the country lists, all products marked with an asterisk contain levonorgestrel as the active progestogen and the noncontraceptive dextronorgestrel. These products are also marked with an asterisk in the list of codes, indicating that they contain twice the amount of progestogen than other products under the same code. Yet, 50% of the progestogen is inactive as a contraceptive, so all the products under the same code can be substituted for each other. Family planning associations, government health departments, manufacturers of contraceptive products, and IPPF's Supplies Department served as key sources for the directory.
GUARDIAN (MANCHESTER, ENGLAND). 1977 Jul 6; 1,6.The injectable contraceptive Depo Provera, banned in the U.S. and other Western countries because of associated cancer risks, is currently being distributed by Western governments in the Third World countries. There are now more than 500,000 women in Asia and Africa who are currently using the contraceptive containing MPA (medroxyprogesterone acetate), which in U.S. Food and Drug Administration trials produced cancers in beagle bitches. The U.S. and Swedish governments, through WHO, IPPF (International Planned Parenthood Federation) and other bodies, are financing the distribution of the contraceptive in Asia. 2 issues are raised by this distribution activity: 1) the ethical issue of using drugs banned in the West on illiterate women in the Third World; and 2) the use of contraceptives on a huge scale, despite FDA warnings and bans in Western countries. Asian doctors have long pointed out that Western companies whose products have been banned in their own countries have been dumping substandard equipment and medicines into the Asian market. Depo Provera, injected every 3 months, is widely used in Southeast Asia, particularly in Thailand. The London-based IPPF is the world's largest distributor of the contraceptive. The Family Planning Association in Britain has applied for the lifting of restrictions in Britain, but the Committee on Safety of Medicines has approved its short-term use only for women whose husbands have had a vasectomy and for women being immunized against German measles. Dr. Malcolm Potts, medical advisor to IPPF, and other research clinics in Britain and in the U.S. questioned the association between beagle trials and women taking far lower doses. Thai women who had been treated with Depo over many years have not shown any increase in cancerous symptoms. However, the real issue behind the controversy is the distribution of Western medicines and drugs in Third World countries. As Dr. Zafrullah Choudhury, founder of the "barefoot doctor" scheme in Bangladesh said, "Western doctors feel they can do experiments on Asian women because they are poor and illiterate. They do not regard them as people. They...see family planning in terms of numbers....in terms of population control rather than people."
London, England, IPPF, April 1983. 9 p. (IPPF Fact Sheet)Discusses the International Planned Parenthood Federation's (IPPF) position on the use of injectable contraceptives. The 2 currently available injectable contraceptives are depot medroxyprogesterone acetate (DMPA), which is marketed under the name Depo-Provera, and norethisterone acetate (NET-EN), sold as Noristerat or Norigest. Injectable contraceptives are highly effective, convenient, and have a long-acting effect which is an advantage. DMPA has been approved for contraceptive use in more than 80 developing and developed countries, and NEP-EN, a recent introduction, in 40 countries. After the contraceptive has been approved for domestic use, it is supplied by IPPF to those countries which request it. Injectables are also provided for contraceptive use by the World Health Organization (WHO) and the United Nations Fund for Population Activities (UNFPA). The current positions of the WHO and the IPPF are covered, as well as the positions of Britain, Sweden, and the United States. Criticisms of the injectable contraceptives and IPPF's position regarding these are also discussed. After taking the criticisms into account, IPPF concludes that there is not sufficient reason to change its current position on injectable contraceptives. It will continue to keep all methods under close and continuous review.